Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: insights from the Acarbose Cardiovascular Evaluation (ACE) trial
<p><strong>Aims:</strong> Heart failure is a fatal complication of type 2 diabetes but little is known about its incidence in people with impaired glucose tolerance (IGT). We used Acarbose Cardiovascular Evaluation (ACE) trial data to identify predictors of hospitalisation for hear...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2020
|
| _version_ | 1826309247727566848 |
|---|---|
| author | Wamil, M McMurray, JJV Scott, CAB Coleman, RL Sun, Y Standl, E Rydén, L Holman, RR |
| author_facet | Wamil, M McMurray, JJV Scott, CAB Coleman, RL Sun, Y Standl, E Rydén, L Holman, RR |
| author_sort | Wamil, M |
| collection | OXFORD |
| description | <p><strong>Aims:</strong> Heart failure is a fatal complication of type 2 diabetes but little is known about its incidence in people with impaired glucose tolerance (IGT). We used Acarbose Cardiovascular Evaluation (ACE) trial data to identify predictors of hospitalisation for heart failure (hHF) or cardiovascular (CV) death in patients with coronary heart disease (CHD) and IGT randomised to acarbose or placebo.</p>
<p><strong>Methods:</strong> Independent hHF/CV death risk factors were determined using Cox proportional hazards models, with participants censored at first hHF event, CV death, or end of follow-up.</p>
<p><strong>Results:</strong> During median 5-year follow-up, the composite outcome of hHF/CV death occurred in 393 (6.0%) participants. Significant hHF/CV death multivariate predictors were higher age and plasma creatinine, and prior heart failure (HF), myocardial infarction (MI), atrial fibrillation (AF) and stroke. Acarbose, compared with placebo, did not reduce hHF/CV death (hazard ratio [HR] 0.89, 95% CI 0.64–1.24, P = 0.48) or hHF (HR 0.90, 95% CI 0.74–1.10, P = 0.32).</p>
<p><strong>Conclusions:</strong> Patients with CHD and IGT at greater risk of hHF/CV death were older with higher plasma creatinine, prior HF, MI, AF or stroke. Addition of acarbose to optimised CV therapy to reduce post-prandial glucose excursions did not reduce the risk of hHF/CV death or hHF.</p>
<p><strong>Clinical Trial Registration:</strong> ClinicalTrials.gov, number NCT00829660, and the International Standard Randomised Controlled Trial Number registry, number ISRCTN91899513.</p> |
| first_indexed | 2024-03-07T07:31:19Z |
| format | Journal article |
| id | oxford-uuid:0c1d1a25-f81e-4ba6-a184-1f7524d47ae2 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:31:19Z |
| publishDate | 2020 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:0c1d1a25-f81e-4ba6-a184-1f7524d47ae22023-01-31T10:27:44ZPredicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: insights from the Acarbose Cardiovascular Evaluation (ACE) trialJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:0c1d1a25-f81e-4ba6-a184-1f7524d47ae2EnglishSymplectic ElementsElsevier2020Wamil, MMcMurray, JJVScott, CABColeman, RLSun, YStandl, ERydén, LHolman, RR<p><strong>Aims:</strong> Heart failure is a fatal complication of type 2 diabetes but little is known about its incidence in people with impaired glucose tolerance (IGT). We used Acarbose Cardiovascular Evaluation (ACE) trial data to identify predictors of hospitalisation for heart failure (hHF) or cardiovascular (CV) death in patients with coronary heart disease (CHD) and IGT randomised to acarbose or placebo.</p> <p><strong>Methods:</strong> Independent hHF/CV death risk factors were determined using Cox proportional hazards models, with participants censored at first hHF event, CV death, or end of follow-up.</p> <p><strong>Results:</strong> During median 5-year follow-up, the composite outcome of hHF/CV death occurred in 393 (6.0%) participants. Significant hHF/CV death multivariate predictors were higher age and plasma creatinine, and prior heart failure (HF), myocardial infarction (MI), atrial fibrillation (AF) and stroke. Acarbose, compared with placebo, did not reduce hHF/CV death (hazard ratio [HR] 0.89, 95% CI 0.64–1.24, P = 0.48) or hHF (HR 0.90, 95% CI 0.74–1.10, P = 0.32).</p> <p><strong>Conclusions:</strong> Patients with CHD and IGT at greater risk of hHF/CV death were older with higher plasma creatinine, prior HF, MI, AF or stroke. Addition of acarbose to optimised CV therapy to reduce post-prandial glucose excursions did not reduce the risk of hHF/CV death or hHF.</p> <p><strong>Clinical Trial Registration:</strong> ClinicalTrials.gov, number NCT00829660, and the International Standard Randomised Controlled Trial Number registry, number ISRCTN91899513.</p> |
| spellingShingle | Wamil, M McMurray, JJV Scott, CAB Coleman, RL Sun, Y Standl, E Rydén, L Holman, RR Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: insights from the Acarbose Cardiovascular Evaluation (ACE) trial |
| title | Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: insights from the Acarbose Cardiovascular Evaluation (ACE) trial |
| title_full | Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: insights from the Acarbose Cardiovascular Evaluation (ACE) trial |
| title_fullStr | Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: insights from the Acarbose Cardiovascular Evaluation (ACE) trial |
| title_full_unstemmed | Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: insights from the Acarbose Cardiovascular Evaluation (ACE) trial |
| title_short | Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: insights from the Acarbose Cardiovascular Evaluation (ACE) trial |
| title_sort | predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance insights from the acarbose cardiovascular evaluation ace trial |
| work_keys_str_mv | AT wamilm predictingheartfailureeventsinpatientswithcoronaryheartdiseaseandimpairedglucosetoleranceinsightsfromtheacarbosecardiovascularevaluationacetrial AT mcmurrayjjv predictingheartfailureeventsinpatientswithcoronaryheartdiseaseandimpairedglucosetoleranceinsightsfromtheacarbosecardiovascularevaluationacetrial AT scottcab predictingheartfailureeventsinpatientswithcoronaryheartdiseaseandimpairedglucosetoleranceinsightsfromtheacarbosecardiovascularevaluationacetrial AT colemanrl predictingheartfailureeventsinpatientswithcoronaryheartdiseaseandimpairedglucosetoleranceinsightsfromtheacarbosecardiovascularevaluationacetrial AT suny predictingheartfailureeventsinpatientswithcoronaryheartdiseaseandimpairedglucosetoleranceinsightsfromtheacarbosecardiovascularevaluationacetrial AT standle predictingheartfailureeventsinpatientswithcoronaryheartdiseaseandimpairedglucosetoleranceinsightsfromtheacarbosecardiovascularevaluationacetrial AT rydenl predictingheartfailureeventsinpatientswithcoronaryheartdiseaseandimpairedglucosetoleranceinsightsfromtheacarbosecardiovascularevaluationacetrial AT holmanrr predictingheartfailureeventsinpatientswithcoronaryheartdiseaseandimpairedglucosetoleranceinsightsfromtheacarbosecardiovascularevaluationacetrial |